On Wednesday, Interphase Corporation (NASDAQ:INPH)’s shares declined -16.67% to $0.510.
Interphase Corporation (INPH) stated financial results for its first quarter ended March 31, 2015.
Revenues for the first quarter of 2015 were $2.1 million, a decrease of 39% when contrast to revenues from the first quarter of 2014 of $3.4 million. Revenues in the quarter were primarily derived from communications networking product revenues, which reduced 14% to $1.5 million in the first quarter of 2015 contrast to $1.7 million for the first quarter of 2014. In addition, services revenues reduced 70% to $500,000 in the first quarter of 2015 contrast to $1.6 million in the first quarter of 2014. Gross margin was 30% for the first quarter of 2015 contrast to 31% for the first quarter of 2014. The Company stated a net loss of $1.5 million, or ($0.18) per share in the first quarter of 2015 contrast to a net loss of $1.0 million, or ($0.14) per share in the first quarter of 2014. On March 31, 2015, the Company’s working capital position was $3.9 million, counting cash of $2.3 million.
Interphase Corporation, an information and communications technology company, provides embedded computing solutions, engineering design services, and contract manufacturing services in North America, the Pacific Rim, and Europe.
Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s shares dropped -15.35% to $5.02.
Orexigen Therapeutics, Inc. (OREX) issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that contrast the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, and an update on its Contrave partnershipwith Takeda Pharmaceuticals Company.
Since continuation of the Light Study was not a postmarketing requirement (PMR), and the majority of patients are no longer on blinded study drug, Orexigen had long advocated shutting down the study in December 2014, corresponding with the time of the 50% interim analysis, and focusing resources on new studies to further evaluate the therapeutic profile of Contrave.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a partnershipagreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico.
At the end of Wednesday’s trade, ResMed Inc. (NYSE:RMD)‘s shares dipped -15.13% to $55.48.
ResMed Inc. (RMD) declared that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.
The study did not show a statistically noteworthydifference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure (based on a hazard ratio [HR] = 1.136, 95 percent confidence interval [95% CI] = (0.974, 1.325), p-value = 0.104). The results from SERVE-HF are preliminary and will be presented for future publication after further analysis.
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and administration of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio comprises airflow generators, diagnostic products, mask systems, motors, and headgear, in addition to other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages.
Atlatsa Resources Corp (USA) (NYSEMKT:ATL), ended its Wednesday’s trading session with -14.73% loss, and closed at $0.110.
Atlatsa Resources Corp (USA) (ATL) confirms that operations at the Bokoni Platinum Mine (“Bokoni”) have been interrupted by the recent unrest that erupted in the Bokoni area.
The unrest began yesterday, Monday 11 May 2015, when some members of the community surrounding Bokoni blocked the main road leading to Bokoni with burning tyres and rocks. Employees were prevented from reporting for work as a result of the blockade and intimidation. Bokoni also confirms that there was damage to the timber storage yard and to the network and telephone infrastructure. Bokoni administration is working closely with the South African Police Services to ensure safety and security in the region.
Atlatsa Resources Corporation mines and explores for platinum group metal properties in South Africa. The company primarily explores for platinum, palladium, rhodium, gold, copper, and nickel. It holds interests in the Bokoni Mine property covering an area of 19,123.16 hectares located in the Sekhukhuneland district of the Limpopo province; and the Platreef project comprising the Central Block, the Rietfontein Block, and the Kwanda project, which are located on the Northern Limb of the Bushveld Igneous Complex in South Africa.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
